

Patient Case Study


PANCREATIC CANCER PATIENT WITH COMPLETE RESPONSE

PET-CT of the pancreatic tumor after 30 days demonstrates minimal SUV uptake at lesion, potential post-treatment inflammation distal to treated lesion. PET-CT after 90 days demonstrates no PET activity and no further inflammation.



LIVER METASTASIS RESPONSE TO TREATMENT OF PANCREATIC TUMOR

90 days post treatment of the primary pancreatic tumor, a metastatic liver lesion no longer remains evident on PET-CT despite no change in systemic therapy.



POTENTIAL BENEFITS OF ALPHA DART TREATMENT FOR LOCALLY ADVANCED & METASTATIC PANCREATIC CANCER*



Increased Survival

Observed increased median survival



Well-Tolerated Safety Profile

Minimal serious related adverse events reported



Minimally-Invasive Procedure

Treatment generally performed under local anesthesia



Intratumoral Therapy

Direct source delivery via standard endoscopic US guided outpatient procedure



Pain Relief

Usually seen within a few days

Compatible with Standard of Care

Can be used in combination with SoC chemotherapy or as a monotherapy

* Based on interim studies